Key Takeaways
- Shares of Regenxbio tumbled 25% to $8.05 following an FDA clinical hold announcement for RGX-121 gene therapy
- Asymptomatic spinal nodules or cystic masses were detected in five participants during enhanced MRI surveillance
- Medical evaluators categorized the discoveries as non-serious with likely benign characteristics
- The biotech firm has withdrawn near-term plans for BLA resubmission of RGX-121
- Development continues for the company’s Duchenne therapy with a BLA submission planned this quarter, plus wet AMD data expected in Q4
Shares of Regenxbio plummeted 25% to $8.05 during Monday’s trading session after federal regulators imposed a clinical hold on RGX-121, the company’s experimental gene therapy targeting Hunter syndrome. The announcement prompted a temporary trading suspension before the news broke.
The regulatory action followed results from an enhanced MRI surveillance initiative that identified unexpected findings in five trial participants. Each individual presented with a small nodular formation or cystic structure along their spinal column. These patients had undergone RGX-121 administration approximately three to six years before the imaging abnormalities emerged.
Medical investigators labeled the observations as non-serious adverse events. Radiological specialists determined the masses were most likely benign in nature, with no definitive clinical or pathological data establishing a causal relationship to the experimental treatment.
Despite these characterizations, federal regulators proceeded with the clinical hold, prompting Regenxbio to announce it has abandoned expectations for near-term BLA resubmission for RGX-121.
Just three months ago in June, the FDA had informed Regenxbio that no supplementary clinical studies would be required before proceeding with a third-quarter BLA resubmission. That regulatory pathway has now been completely derailed.
This marks the second Regenxbio therapeutic program halted by federal regulators in the past several months. RGX-111, another candidate in development, faced a clinical hold earlier this year, mere weeks before an anticipated approval determination. That initial hold was subsequently broadened to include RGX-121 due to therapeutic similarities between the two investigational treatments.
Management Response
Chief Executive Officer Curran Simpson characterized the imaging discoveries as “unique and limited” to the Hunter syndrome development program, while recognizing they “require longer-term follow-up and additional data analysis” before the organization can comprehensively evaluate RGX-121’s benefit-risk equation.
All five affected participants continue demonstrating overall stability or progressive improvement in neurocognitive and neurobehavioral testing metrics.
Hunter syndrome represents a rare inherited metabolic condition characterized by the body’s inability to process complex sugar molecules properly. The disorder predominantly impacts male patients and severely limits lifespan, with most individuals surviving only into their twenties.
Pipeline Remains Active
The company emphasized that its Duchenne muscular dystrophy and wet age-related macular degeneration development programs utilize different capsid technology and administration routes, leaving them unaffected by the regulatory hold.
Management reaffirmed plans to file a BLA for the Duchenne therapeutic candidate during the ongoing quarter.
Primary endpoint data for the wet AMD investigational treatment, being co-developed alongside AbbVie, remains scheduled for Q4 release. Wall Street analysts have identified this data readout as a potentially significant catalyst for Regenxbio’s stock performance.
Competing biotechnology companies experienced spillover effects from the announcement. Sarepta Therapeutics declined 3.3% while EyePoint shares retreated 4.3% during the trading session.
Earlier in the current month, Barclays analyst Eliana Merle revised her rating on Regenxbio to Equal Weight from Overweight, pointing to regulatory uncertainty and intensifying competitive pressures as material risks confronting both development programs.
Management disclosed ongoing collaboration with development partner NS Pharma to assess supplementary patient imaging results and extended follow-up information, with plans to integrate FDA guidance into the strategic roadmap for RGX-121’s future development.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
